CRISPR is a technology that can be used to edit genes and, as such, will likely change the world. The essence of CRISPR is simple: it’s a way of finding a specific bit of DNA inside a cell.

Scientists and policymakers are meeting in Washington, DC December 1-3 to debate the use of CRISPR/Cas9, a tool that makes it possible to make changes to an organism's DNA almost as easily as ...

CRISPR stocks are high risk but hold potential for aggressive investors. CRISPR Therapeutics and its partner Vertex Pharmaceuticals have the only approved CRISPR therapy. Several other biotech ...

The idea behind the notorious CRISPR-baby scandal, editing reproductive cells or ... The method has been available since 2019, explained Carmi, Greely, and Mitchell, “but the expected reductions in ...

CRISPR Therapeutics' stock decline is likely influenced by Editas Medicine's struggles, but CRISPR remains a distinct and stronger company with a promising long-term outlook. CRISPR's strategic ...

Results prove that inversions can be generated in plants without causing further unwanted changes in the expression of genetic information.

Leerink Partnrs boosted their FY2024 earnings per share (EPS) estimates for CRISPR Therapeutics in a note issued to investors ...

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform.

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $43.42, moving -1.83% from the previous trading session.